スマート医療機器市場

The secondary research process involved comprehensive analysis of medical device regulatory frameworks, digital health standards, clinical evidence databases, and connected care infrastructure reports. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) and Digital Health Center of Excellence, European Medicines Agency (EMA) Medical Device Coordination Group (MDCG), International Organization for Standardization (ISO) Technical Committee 215 (Health Informatics) and IEC 62304 (Medical Device Software) standards, World Health Organization (WHO) Digital Health Initiative and Global Observatory on Health Research and Development, Centers for Medicare & Medicaid Services (CMS) Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) coverage decisions, National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB), Advanced Medical Technology Association (AdvaMed), MedTech Europe, Healthcare Information and Management Systems Society (HIMSS), IEEE Standards Association ( wearables and body area networks), ClinicalTrials.gov (interventional studies on connected devices), PubMed/MEDLINE (digital biomarker validation studies), Health Canada Medical Devices Active Licence Listing (MDALL), Pharmaceuticals and Medical Devices Agency (PMDA) Japan (software as medical device guidelines), National Medical Products Administration (NMPA) China, OECD Health Statistics, and World Bank Digital Development indicators.

These sources were employed to gather data on the following: cybersecurity guidance compliance, interoperability standards (HL7 FHIR, Continua), chronic disease prevalence fueling adoption, and reimbursement landscape evolution for remote patient monitoring. Additionally, connected device approval data (510(k), De Novo, CE-MDR), and cybersecurity guidance compliance (510(k)) were collected.

During the primary research process, qualitative and quantitative insights regarding device connectivity, cybersecurity implementation, and clinical workflow integration were obtained through interviews with supply-side and demand-side stakeholders. In addition to regulatory affairs specialists for SaMD (Software as Medical Device), supply-side sources included commercial leaders from wearable manufacturers, implantable device OEMs, and remote monitoring platform providers, as well as vice presidents of digital health and chief technology officers. Cardiologists, endocrinologists (diabetes technology specialists), hospital chief innovation officers, health system telemedicine directors, and procurement leads from ambulatory surgical centers and integrated delivery networks (IDNs) constituted demand-side sources. Primary research has confirmed the timelines for AI/ML algorithm validation, validated market segmentation across diagnostic monitoring, therapeutic delivery, and rehabilitation devices, and gathered insights on data privacy compliance (HIPAA/GDPR), cloud vs. edge computing preferences, and payor contracting strategies for connected care models.

Primary Respondent Breakdown:

By Designation: C-level Executives (40%), Director Level (30%), Others (30%)

By Region: North America (38%), Europe (25%), Asia-Pacific (30%), Rest of World (7%)

The global market valuation was determined by analyzing recurring software revenue, monitoring connected device shipments, and modeling ASP across hardware/software bundles. The methodology comprised the following:

Identification of over 50 key manufacturers in North America, Europe, Asia-Pacific, and Latin America, including traditional medical device multinationals, consumer health tech crossover entities, and connected sensor specialists

The following is a product mapping of diagnostic monitoring devices (continuous glucose monitors, smart ECG patches, connected inhalers), therapeutic devices (smart insulin pumps, automated insulin delivery systems, connected neurostimulators), and rehabilitation/portable devices (smart wound care sensors, connected orthopedic braces, medication adherence monitors).

An examination of the annual revenues of smart/connected device portfolios, which include hardware sales, SaaS subscription revenue, and remote monitoring service fees, as reported and modeled.

Manufacturers that account for 65-70% of the global market share in 2024 are included in the coverage.

Derive segment-specific valuations for wearable, implantable, and stationary smart device categories through extrapolation using bottom-up (device shipment volume × blended ASP by country, including hardware plus average 12-month software subscription) and top-down (manufacturer IoT/connected health revenue validation) approaches.